ASH 2019: Initial results of a phase II study investigating Tazemetostat for treatment of relapsed follicular lymphoma.
Home / Resource Library / Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor, in Patients with Relapsed or Refractory Follicular Lymphoma